phase 1_completion
saveNational Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)
community read0 votes
Therapy area: Gastrointestinal, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Hepatocellular Carcinoma, Liver Cancer, Liver Cirrhosis, Metastatic Liver Cancer
Data sources
globaldata
Found something off?
drug timeline · 1
same company · ±60 days · 6
- phase 1 initiationAutologous B7-H3 CAR T: National Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Apr 27, 2026
- phase 2 initiationbusulfan: National Cancer Institute US — busulfan (Phase II Trial Initiation)Apr 27, 2026
- phase 2 initiationcyclophosphamide: National Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)Apr 27, 2026
- phase 1 2 initiationsacituzumab govitecan: National Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)Apr 27, 2026
- phase 2 initiation(daratumumab + hyaluronidase (human recombinant)): National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)Apr 29, 2026
- phase 2 completionipilimumab: National Cancer Institute US — ipilimumab (Phase II Trial Completion)Apr 30, 2026
🐶 often sniffed alongside
top 7- tagOncology7 co-mentions · 2 sources
- tagHepatology3 co-mentions · 1 sources
- drugUndisclosed2 co-mentions · 2 sources
- tagNSCLC1 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
- companyNucleic Acids to the Rescue GmbH1 co-mentions · 1 sources
- tagPulmonology1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that